These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6426771)

  • 1. Tamoxifen treatment of metastatic breast cancer and antithrombin III levels.
    Enck RE; Rios CN
    Cancer; 1984 Jun; 53(12):2607-9. PubMed ID: 6426771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels.
    Bertelli G; Pronzato P; Amoroso D; Cusimano MP; Conte PF; Montagna G; Bertolini S; Rosso R
    Breast Cancer Res Treat; 1988 Dec; 12(3):307-10. PubMed ID: 3228593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III.
    Jordan VC; Fritz NF; Tormey DC
    Cancer Res; 1987 Aug; 47(16):4517-9. PubMed ID: 3607780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tamoxifen on blood coagulation.
    Auger MJ; Mackie MJ
    Cancer; 1988 Apr; 61(7):1316-9. PubMed ID: 3345487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
    Ellmén J; Hakulinen P; Partanen A; Hayes DF
    Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy.
    Love RR; Surawicz TS; Williams EC
    Arch Intern Med; 1992 Feb; 152(2):317-20. PubMed ID: 1739360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
    Decensi A; Robertson C; Viale G; Pigatto F; Johansson H; Kisanga ER; Veronesi P; Torrisi R; Cazzaniga M; Mora S; Sandri MT; Pelosi G; Luini A; Goldhirsch A; Lien EA; Veronesi U
    J Natl Cancer Inst; 2003 Jun; 95(11):779-90. PubMed ID: 12783932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters.
    Morgan LR; Schein PS; Woolley PV; Hoth D; Macdonald J; Lippman M; Posey LE; Beazley RW
    Cancer Treat Rep; 1976 Oct; 60(10):1437-43. PubMed ID: 191185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.
    Rutqvist LE; Mattsson A
    J Natl Cancer Inst; 1993 Sep; 85(17):1398-406. PubMed ID: 8350363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
    Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
    Minerva Ginecol; 2003 Feb; 55(1):87-93. PubMed ID: 12598849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
    Mäenpää JU; Ala-Fossi SL
    Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral contraceptive agents and antithrombin III].
    Kamenov V; Nalbanski B
    Akush Ginekol (Sofiia); 1990; 29(1):60-3. PubMed ID: 1695492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The serum estradiol concentration is the main determinant of the estradiol concentration in normal breast tissue.
    Depypere HT; Bolca S; Bracke M; Delanghe J; Comhaire F; Blondeel P
    Maturitas; 2015 May; 81(1):42-5. PubMed ID: 25721699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen in premenopausal patients with metastatic breast cancer: a review.
    Sunderland MC; Osborne CK
    J Clin Oncol; 1991 Jul; 9(7):1283-97. PubMed ID: 2045868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
    Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
    Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen in postmenopausal women a safety perspective.
    Robinson E; Kimmick GG; Muss HB
    Drugs Aging; 1996 May; 8(5):329-37. PubMed ID: 8935395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
    Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
    J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in serum estrogen levels in women during tamoxifen therapy.
    Lum SS; Woltering EA; Fletcher WS; Pommier RF
    Am J Surg; 1997 May; 173(5):399-402. PubMed ID: 9168075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.